#Imfinzi

New results from the AEGEAN clinical trial offer good news to people with non-small cell lung cancer.

Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.

People treated with a durvalumab-based regimen before and after surgery had a 32% lower risk of disease recurrence or progression.

Thanks to groundbreaking immunotherapy research, Jane Hart enjoys every day without laryngeal cancer.

Adding radiation therapy to Imfinzi and tremelimumab didn’t help those with non-small cell lung cancer, according to a new study.

Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.

Imfinzi plus chemotherapy led to a modest but significant improvement in overall survival.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Additions of the checkpoint inhibitor led to improved survival compared with chemotherapy alone.

Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease.

After finding a protein that smoking affects to drive head and neck cancer, investigators hope manipulating it will prove beneficial.

Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.

A third of patients taking neoadjuvant Opdivo for inoperable advanced liver cancer had complete responses in an early analysis.

Seventy percent of liver cancer patients had either a partial response or stable disease.

Checkpoint inhibitor alone or in combination shows benefits for different types of colorectal cancer.